PT  - JOURNAL ARTICLE
AU  - Santos da Silva, Eveline
AU  - Kohnen, Michel
AU  - Gilson, Georges
AU  - Staub, Therese
AU  - Arendt, Victor
AU  - Hilger, Christiane
AU  - Servais, Jean-Yves
AU  - Charpentier, Emilie
AU  - Domingues, Olivia
AU  - Snoeck, Chantal J.
AU  - Ollert, Markus
AU  - Seguin-Devaux, Carole
AU  - Perez-Bercoff, Danielle
TI  - Pre-Omicron vaccine breakthrough infection induces superior cross-neutralization against SARS-CoV-2 Omicron BA.1 than primo infection
AID  - 10.1101/2022.06.21.22276659
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.21.22276659
4099  - http://medrxiv.org/content/early/2022/06/23/2022.06.21.22276659.short
4100  - http://medrxiv.org/content/early/2022/06/23/2022.06.21.22276659.full
AB  - SARS-CoV-2 variants raise concern because of their high transmissibility and their ability to evade neutralizing antibodies elicited by prior infection or by vaccination. Here we compared the ability of sera from 70 unvaccinated COVID-19 patients infected before the emergence of variants of concern (VOCs) and from 16 vaccine breakthrough infection (BTI) cases infected with Gamma or Delta to neutralize the ancestral B.1 strain, and the Gamma, Delta and Omicron BA.1 variants using live virus. We further determined antibody levels against the Spike protein, the Receptor Binding Domain (RBD) and the N-terminal domain (NTD) of Spike. Convalescent sera featured considerable variability in neutralization of B.1 and in cross-neutralization of different strains, and neutralizing capacity moderately correlated with antibody levels against Spike and the RBD. All but one convalescent serum failed to neutralize Omicron BA.1. Overall, convalescent sera from patients with moderate disease had higher antibody levels and displayed higher neutralizing ability against all strains than patients with mild or severe forms of disease. Sera from BTI cases fell into one of two categories: half the sera had high neutralizing activity against the ancestral B.1 strain as well as against the infecting strain, while the other half had no or very low neutralizing activity against all strains. Although antibody levels against Spike and the RBD were lower in BTI cases than in unvaccinated convalescent sera, most neutralizing sera also retained partial neutralizing activity against Omicron BA.1, indicative of cross-neutralization between B.1, Delta and Omicron and suggestive of higher affinity, as confirmed by the IC50:Ab level ratios. Neutralizing activity of BTI sera was strongly correlated with antibodies against Spike and the RBD. Together, these findings highlight qualitative differences in antibody responses elicited by infection in vaccinated and unvaccinated individuals. They further suggest that breakthrough infection with a pre-Omicron variant boosts immunity and induces cross neutralizing antibodies against different strains, including Omicron BA.1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Fonds National de la Recherche du Luxembourg (FNR COVID-19 FT-1 (14718697 NEUTRACOV), by the Rotary Clubs Luxembourg, and by Ministere de l Education et de la Recherche du Luxembourg.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Luxembourg Institute of Health (LIH) Institutional Review Board. Ethical approval was waved for this study due to the use of de-identified leftover samples for the validation of serological and virological assays. De-indentified leftover samples were provided by the Centre Hospitalier de Luxembourg (CHL) following a signed agreement between LIH and CHL. No personal or clinical data was available to the investigators. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript